Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of ADC Rovalpituzumab Tesirine, which has been investigated for the treatment of SCLC.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.